Competitive Range Of One Gets Close Scrutiny
Client Alert | less than 1 min read | 09.25.08
Reviewing the law that an agency's narrowing the competitive range to one results in close scrutiny, the CFC in L-3 Communications Eotech, Inc. v. U.S. (Sept. 23, 2008, http://www.crowell.com/pdf/L3-Communications_v_US-AimPoint_08-515.pdf) proceeded to set aside such a determination when the agency disqualified the protestor based on a failed functional test that it relaxed for the favored offeror. The court, after seeing a live demonstration of the hardware involved, also found irrational the agency's failure to seek clarifications when the protestor's perceived testing problem could have been corrected relatively easily.
Insights
Client Alert | 3 min read | 11.17.26
CMS Final OPPS Rule Will Reduce Reimbursement for 340B Drugs
On November 6, 2026, the Centers for Medicare and Medicaid Services (CMS) published its final 2027 Medicare Hospital Outpatient Perspective Payment System (OPPS) rule. The rule will reduce reimbursement for 340B drugs from average sales price (ASP) plus 6% (what Medicare generally pays for Part B outpatient drugs administered by providers) to ASP minus 28%, a 32% reduction. CMS originally proposed reducing reimbursement to ASP minus 33.4%. CMS indicated that this change will better align Medicare reimbursement with hospitals’ costs of acquiring 340B drugs.
Client Alert | 9 min read | 11.17.26
Priorities and Prospects for AI Legislation in the New Congress
Client Alert | 8 min read | 11.16.26
OCC’s AI Examiner Framework: How Banks’ AI Use Can Trigger Legal Liability and Supervisory Exposure
Client Alert | 3 min read | 11.13.26
Massachusetts Trade Secret Preliminary Injunctions: Prove the Harm, Tailor the Relief
